Maze Therapeutics, Inc. 8K

Maze Therapeutics reported Q2 2026 results, advanced multiple Phase 2 programs for kidney and metabolic diseases, and strengthened its cash runway into 2029 following a $150 million equity offering.

Maze Therapeutics, Inc. reported its unaudited financial results for the quarter ended June 30, 2026 and provided a corporate update, highlighting continued enrollment in its Phase 2 HORIZON trial of MZE829 for APOL1-mediated kidney disease, initiation and ongoing enrollment of the Phase 2 CIPheR trial of MZE782 in phenylketonuria with topline data expected in 2027, plans to start a Phase 2 CKD trial of MZE782 in the first half of 2027 and a pivotal trial of MZE829 in 2027, and a strengthened balance sheet with $494.9 million in cash, cash equivalents and marketable securities following an April 2026 equity and pre-funded warrant offering that provides expected cash runway into 2029, while reporting increased R&D and G&A expenses and a net loss of $44.7 million for the quarter.

Filing Facts

CIK

1842295

Ticker

MAZE

Form

8K

Source Type

fda

Accession

0001193125-26-344878

Alert Tier

6